Thema: US92337C2035
VSTM, US92337C2035
chart-1905225_1920.jpg - Foto: THN
Verastem stock heads toward November 5 results after $250 million offering
Verastem stock is due to report its latest quarterly results. The biotech focuses on medicines for RAS/MAPK-driven cancers.
ad-hoc-news.de, heute 13:43 Uhr
VSTM, US92337C2035
Verastem reports 50 percent response rate. Verastem stock ...
Verastem stock costs EUR 8.89 on October 29, 2026. Third-quarter results are scheduled for November 5, 2026, with revenue guidance of USD 23.9-24.1 million.
ad-hoc-news.de, 29.10.26 13:44 Uhr
VSTM, US92337C2035
BTIG raised target for Verastem Oncology stock from USD ...
BTIG set a USD 24.00 target on October 15, 2026. Verastem Oncology stock costs EUR 8.96 on October 27, 2026, with USD 905.6 million value.
ad-hoc-news.de, 27.10.26 14:22 Uhr
VSTM, US92337C2035
Verastem prices USD 250 million offering of Verastem stock ...
The October 14 financing covered 30.94 million shares at USD 8.00. For Verastem stock, results are set for November 5, 2026.
ad-hoc-news.de, 25.10.26 13:50 Uhr
VSTM, US92337C2035
Verastem Oncology prices USD 250 million offering for Verastem ...
Verastem priced USD 250.00 million offering on October 14, 2026. Verastem Oncology stock traded at EUR 8.16 on October 22, 2026.
ad-hoc-news.de, 22.10.26 13:52 Uhr
VSTM, US92337C2035
Verastem names CEO successor. Verastem Oncology stock has ...
Michael P. Bailey will take over as CEO on January 1, 2027. Verastem Oncology stock costs EUR 7.65 on October 20, 2026, with USD 780.7 million value.
ad-hoc-news.de, 20.10.26 13:57 Uhr
VSTM, US92337C2035
Jefferies raises target for Verastem Oncology stock from ...
VS-7375 posted a 50.00 percent response rate on October 14, 2026. For Verastem Oncology stock, the financing totals USD 250.00 million.
ad-hoc-news.de, 18.10.26 12:40 Uhr
VSTM, US92337C2035
Verastem announces KRAS data and CEO transition for Verastem ...
Verastem reports a 50.00 percent response rate in pancreatic cancer. Verastem stock costs EUR 7.39 on October 15, 2026.
ad-hoc-news.de, 15.10.26 13:28 Uhr
VSTM, US92337C2035
BTIG keeps its Buy rating for Verastem stock
Q2 revenue reached USD 40.08 million versus USD 22.88 million expected. BTIG targets Verastem stock at USD 18.00 on October 5, 2026.
ad-hoc-news.de, 07.10.26 04:17 Uhr
VSTM, US92337C2035
Verastem presents RAMP 201 data. Verastem stock trades at ...
